FDA advisory panel review of KemPharm's lead candidate set for May 5

14 March 2016

US clinical-stage biotech firm KemPharm (Nasdaq: KMPH) says that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the US Food and Drug Administration has been scheduled for May 5, to review its New Drug Application for KP201/APAP, its lead investigational drug candidate for the short-term management of acute pain.

KemPharm’s shares gained 3.2% to $14.50 by mid-morning following the announcement. Analysts have set a 1 year consensus target price of $26.75 for the company and are forecasting that KemPharm will post ($0.56) earnings per share for the current quarter, according to Zacks Equity Research.

Target PDUFA date of June 9

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK